Bend, OR, USA, November 29, 2021 — The newly formed company, Phoenix-Micron, Inc., announced today it has completed the spin-out of the Phoenix MICRON® imaging platform from Phoenix Technology Group. This move is designed to increase focus and innovation in products designed to serve the eye and eye-brain research community. The new company, Phoenix-Micron, Inc.
18.01
2017
Analyzing Choroidal Neovascularization (CNV) in pigs: Saline vs. Eylea™
In the experiment above, pigs received six laser shots per eye, with the control group receiving saline treatment and test group receiving Eylea™ treatment. Eylea™, an FDA-approved drug, is an anti-vascular endothelial growth factor (anti-VEGF) that prevents vascular growth. The crisp, high resoution brightfield and fluorescein angiography images, captured by the Micron X, show that Eylea™ clearly mitigates the neovascularization induced by laser burn.